Home Data Calendar Blog

MORF

Tables

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31
Common Stock Value		0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	NA	NA	NA	NA
Weighted Average Number Of Diluted Shares Outstanding		49.55	42.37	40.11	NA	38.49	39.55	37.13	NA	36.55	36.18	33.53	NA	32.37	30.36	NA	NA	30.00	NA	NA	NA
Weighted Average Number Of Shares Outstanding Basic		49.55	42.37	40.11	NA	38.49	38.24	37.13	NA	36.55	36.18	33.53	NA	30.53	30.36	30.19	NA	30.00	NA	NA	NA
Earnings Per Share Basic		-0.73	-0.92	-0.90	-0.64	-0.78	0.70	-0.85	-0.58	-0.69	-0.77	-0.63	-0.57	0.18	-0.52	-0.55	-0.63	-0.30	NA	NA	NA
Earnings Per Share Diluted		-0.73	-0.92	-0.90	-0.64	-0.78	0.68	-0.85	-0.58	-0.69	-0.77	-0.63	-0.57	0.17	-0.52	-0.55	-0.63	-0.30	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31
Revenue From Contract With Customer Excluding Assessed Tax		0.00	0.00	0.52	6.13	2.06	60.24	2.38	9.56	3.12	3.85	3.27	5.90	25.76	7.69	5.59	-0.33	5.67	5.57	6.07	3.36
Revenue From Contract With Customer Including Assessed Tax		0.00	0.00	0.52	6.13	2.06	60.24	2.38	9.56	3.12	3.85	3.27	5.90	25.76	7.69	5.59	-0.33	5.67	5.57	6.07	3.36
Revenues		0.00	0.00	0.52	6.13	2.06	60.24	2.38	9.56	3.12	3.85	3.27	5.90	25.76	7.69	5.59	-0.33	5.67	5.57	6.07	3.36
Costs And Expenses		44.75	45.30	39.73	32.72	33.55	33.89	34.05	31.10	28.24	31.69	24.57	23.88	20.75	24.11	23.38	20.25	15.53	15.98	12.20	9.33
Research And Development Expense		34.36	35.72	30.45	24.70	25.25	25.65	26.46	23.66	20.97	24.55	18.61	18.75	16.00	19.92	18.96	16.82	12.63	13.91	10.37	7.29
General And Administrative Expense		10.38	9.58	9.28	8.01	8.30	8.23	7.59	7.44	7.28	7.14	5.95	5.13	4.75	4.20	4.42	3.43	2.90	2.08	1.83	2.04
Operating Income Loss		-44.75	-45.30	-39.20	-26.58	-31.49	26.35	-31.67	-21.55	-25.12	-27.84	-21.30	-17.98	5.01	-16.42	-17.79	-20.58	-9.86	-10.42	-6.13	-5.97
Interest Income Expense Nonoperating Net		8.61	6.43	3.10	2.24	1.66	0.48	0.19	0.13	0.08	0.04	0.03	0.11	0.23	0.41	0.89	1.09	1.39	1.12	1.06	0.66
Allocated Share Based Compensation Expense		10.53	10.31	9.58	7.12	7.54	7.62	6.76	5.64	5.79	5.31	4.44	3.02	3.00	2.49	2.54	1.38	0.99	0.67	0.50	0.60
Income Tax Expense Benefit		0.08	0.14	0.03	0.04	0.03	0.00	NA	NA	NA	NA	NA	-0.14	-0.12	-0.15	-0.16	0.34	0.30	0.14	0.13	0.00
Profit Loss		-36.21	-39.01	-36.13	-24.38	-30.02	26.84	-31.48	-21.40	-25.04	-27.82	-21.28	-17.75	5.35	-15.86	-16.75	-19.83	-8.86	-9.43	-5.20	NA
Other Comprehensive Income Loss Net Of Tax		0.20	-0.23	1.65	0.76	-1.68	-0.62	-1.31	-0.39	-0.07	-0.00	0.01	-0.06	-0.19	-0.39	0.57	-0.00	0.01	0.02	0.03	NA
Net Income Loss		-36.21	-39.01	-36.13	-24.38	-30.02	26.84	-31.48	-21.40	-25.04	-27.82	-21.28	-17.75	5.35	-15.86	-16.75	-19.83	-8.86	-9.43	-5.20	-5.34
Comprehensive Income Net Of Tax		-36.01	-39.24	-34.48	-23.62	-31.70	26.22	-32.79	-21.79	-25.11	-27.82	-21.28	-17.80	5.16	-16.25	-16.18	-19.83	-8.86	-9.42	-5.17	-5.34

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31
Assets		743.60	748.72	441.95	368.59	389.18	413.88	397.07	426.29	438.56	439.48	459.57	242.38	221.58	212.00	229.16	247.44	260.08	178.61	NA	189.31
Liabilities		20.43	19.36	15.43	19.47	24.12	25.89	83.70	89.59	88.40	91.57	90.67	97.19	91.27	97.08	101.02	106.52	100.73	104.78	NA	102.05
Liabilities And Stockholders Equity		743.60	748.72	441.95	368.59	389.18	413.88	397.07	426.29	438.56	439.48	459.57	242.38	221.58	212.00	229.16	247.44	260.08	178.61	NA	189.31
Stockholders Equity		723.17	729.36	426.51	349.12	365.06	387.99	313.37	336.70	350.17	347.91	368.89	145.20	130.30	114.92	128.13	140.92	159.35	-65.98	-57.23	-52.55

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31
Assets Current		738.10	742.62	435.75	362.18	382.41	406.62	389.49	418.33	435.40	436.85	456.85	239.44	218.40	208.61	225.55	243.57	257.04	172.79	NA	187.12
Cash And Cash Equivalents At Carrying Value		74.23	217.28	41.90	59.27	84.96	141.18	119.84	171.43	184.16	399.40	395.99	102.05	98.08	133.12	107.03	101.56	159.81	44.20	42.42	185.90
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents		74.79	217.84	42.46	59.83	85.52	141.74	120.40	171.99	184.72	399.68	396.26	102.32	98.36	133.40	107.31	101.83	160.08	44.47	42.69	186.18
Accounts Receivable Net Current		NA	NA	0.51	0.46	0.66	1.04	2.04	2.31	2.62	1.31	2.76	7.31	1.64	3.53	3.69	3.47	2.36	0.94	NA	NA
Prepaid Expense And Other Assets Current		13.03	11.27	13.96	13.48	9.99	8.02	6.80	7.89	5.21	3.91	5.77	3.86	3.62	2.54	2.86	3.09	2.93	1.44	NA	1.22
Available For Sale Securities Debt Securities		650.84	514.08	379.38	288.98	286.80	256.38	260.81	236.70	243.42	NA	NA	126.22	NA	NA	NA	NA	NA	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31
Property Plant And Equipment Gross		NA	NA	NA	7.30	NA	NA	NA	6.76	NA	NA	NA	5.76	NA	NA	NA	5.47	NA	NA	NA	3.05
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment		NA	NA	NA	5.18	NA	NA	NA	4.18	NA	NA	NA	3.15	NA	NA	NA	2.03	NA	NA	NA	1.21
Property Plant And Equipment Net		2.28	2.51	2.24	2.12	2.17	2.37	2.37	2.58	2.58	2.33	2.39	2.61	2.82	3.02	3.22	3.45	2.72	2.53	NA	1.84
Other Assets Noncurrent		0.18	0.20	0.23	0.21	0.20	0.15	0.16	0.01	0.01	0.03	0.05	0.07	0.09	0.09	0.11	0.14	0.05	3.02	NA	0.06
Available For Sale Debt Securities Amortized Cost Basis		652.53	515.97	381.04	292.29	290.87	258.77	262.58	237.16	243.48	NA	NA	126.21	NA	NA	NA	NA	NA	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31
Liabilities Current		19.30	17.81	13.48	17.13	18.59	19.68	43.79	38.26	41.76	34.91	34.07	39.44	35.58	45.28	36.84	35.35	26.48	43.53	NA	34.90
Accounts Payable Current		5.27	3.66	5.48	3.48	4.37	3.88	3.50	4.80	3.18	5.25	2.27	3.85	3.02	3.88	4.62	5.17	3.29	2.91	NA	1.75
Accounts Payable And Accrued Liabilities Current		14.03	14.15	8.00	13.18	10.87	11.35	9.99	12.84	8.42	7.69	7.20	10.16	7.46	8.29	5.62	6.64	5.05	5.22	NA	3.24
Accrued Liabilities Current		1.01	0.98	0.75	0.85	0.78	1.48	0.94	0.96	1.01	0.97	1.25	0.68	0.96	0.82	0.72	1.01	1.17	1.68	NA	0.71
Contract With Customer Liability Current		NA	NA	NA	0.47	3.35	4.45	30.31	20.63	30.15	21.80	24.42	25.27	NA	NA	NA	NA	NA	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31
Operating Lease Liability Noncurrent		1.14	1.55	1.95	2.34	2.73	3.11	3.48	3.84	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31
Stockholders Equity		723.17	729.36	426.51	349.12	365.06	387.99	313.37	336.70	350.17	347.91	368.89	145.20	130.30	114.92	128.13	140.92	159.35	-65.98	-57.23	-52.55
Common Stock Value		0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	NA	NA	NA	NA
Additional Paid In Capital		1133.33	1103.52	761.43	649.55	641.87	633.10	584.69	575.23	566.91	539.54	532.70	287.73	255.03	244.81	241.78	238.38	236.98	2.80	NA	1.63
Retained Earnings Accumulated Deficit		-408.45	-372.24	-333.23	-297.10	-272.72	-242.70	-269.54	-238.05	-216.65	-191.61	-163.80	-142.51	-124.76	-130.12	-114.26	-97.51	-77.68	-68.82	NA	-54.19
Accumulated Other Comprehensive Income Loss Net Of Tax		-1.72	-1.92	-1.69	-3.34	-4.10	-2.42	-1.79	-0.48	-0.09	-0.02	-0.02	-0.02	0.03	0.22	0.61	0.04	NA	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31
Net Cash Provided By Used In Operating Activities		-29.25	-23.03	-31.45	-25.12	-24.89	-22.82	-28.15	-20.59	-24.58	-17.91	-20.39	-14.42	3.73	-16.36	-18.94	-14.07	-13.70	-14.07	0.19	92.56
Net Cash Provided By Used In Investing Activities		-133.08	-133.22	-88.40	-1.15	-32.51	3.28	-26.07	5.19	-211.96	19.85	73.75	-11.29	-46.05	41.91	23.62	-44.20	34.20	17.68	-143.67	-0.16
Net Cash Provided By Used In Financing Activities		19.29	331.63	102.48	0.57	1.18	40.88	2.63	2.67	21.58	1.48	240.58	29.68	7.28	0.54	0.80	0.03	95.10	NA	NA	-0.41

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31
Net Cash Provided By Used In Operating Activities		-29.25	-23.03	-31.45	-25.12	-24.89	-22.82	-28.15	-20.59	-24.58	-17.91	-20.39	-14.42	3.73	-16.36	-18.94	-14.07	-13.70	-14.07	0.19	92.56
Net Income Loss		-36.21	-39.01	-36.13	-24.38	-30.02	26.84	-31.48	-21.40	-25.04	-27.82	-21.28	-17.75	5.35	-15.86	-16.75	-19.83	-8.86	-9.43	-5.20	-5.34
Profit Loss		-36.21	-39.01	-36.13	-24.38	-30.02	26.84	-31.48	-21.40	-25.04	-27.82	-21.28	-17.75	5.35	-15.86	-16.75	-19.83	-8.86	-9.43	-5.20	NA
Increase Decrease In Accounts Receivable		0.00	-0.51	0.05	-0.21	-0.37	-1.00	-0.27	-0.31	1.30	-1.45	-4.55	5.68	-1.90	-0.15	0.22	1.10	1.42	0.57	0.38	NA
Increase Decrease In Accounts Payable		1.60	-1.66	2.00	-1.03	0.50	0.28	-1.30	1.81	-2.22	2.94	-1.57	0.82	-0.84	-0.74	-0.31	1.62	0.38	0.02	1.14	-0.00
Share Based Compensation		10.53	10.31	9.58	7.12	7.54	7.62	6.76	5.64	5.79	5.31	4.44	3.02	3.00	2.49	2.54	1.38	0.99	0.67	0.50	0.60

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31
Net Cash Provided By Used In Investing Activities		-133.08	-133.22	-88.40	-1.15	-32.51	3.28	-26.07	5.19	-211.96	19.85	73.75	-11.29	-46.05	41.91	23.62	-44.20	34.20	17.68	-143.67	-0.16
Payments To Acquire Property Plant And Equipment		0.30	0.29	0.55	0.06	0.25	0.00	0.05	0.46	0.36	0.15	0.05	0.07	0.09	0.09	0.29	0.71	0.39	0.50	0.56	0.17

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31
Net Cash Provided By Used In Financing Activities		19.29	331.63	102.48	0.57	1.18	40.88	2.63	2.67	21.58	1.48	240.58	29.68	7.28	0.54	0.80	0.03	95.10	NA	NA	-0.41

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31
Revenues		0.00	0.00	0.52	6.13	2.06	60.24	2.38	9.56	3.12	3.85	3.27	5.90	25.76	7.69	5.59	-0.33	5.67	5.57	6.07	3.36
Abb Vie		NA	NA	NA	NA	NA	0.00	20.00	NA	20.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Abb Vie, License		NA	NA	NA	0.36	0.89	58.44	0.81	6.20	1.48	2.07	1.50	-12.33	23.65	5.29	NA	NA	NA	NA	NA	NA
Janssen Pharmaceuticals Inc, Reimbursement Revenue		0.00	0.00	0.05	0.46	0.66	1.03	1.01	1.03	1.28	1.31	1.32	1.44	1.63	1.84	NA	NA	NA	NA	NA	NA
Janssen Pharmaceuticals Inc, Upfront Payment Revenue		0.00	0.00	0.47	5.32	0.50	0.76	0.56	2.37	0.37	0.47	0.44	0.74	0.48	0.56	NA	NA	NA	NA	NA	NA
Janssen Pharmaceuticals Inc, Upfront Payment Revenue First Two Programs		NA	NA	NA	NA	NA	0.00	10.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Janssen Pharmaceuticals Inc, License		0.00	0.00	0.52	5.78	1.17	1.79	1.57	3.40	1.65	1.78	1.77	2.17	2.11	2.40	NA	NA	NA	NA	NA	NA
Revenue From Contract With Customer Excluding Assessed Tax		0.00	0.00	0.52	6.13	2.06	60.24	2.38	9.56	3.12	3.85	3.27	5.90	25.76	7.69	5.59	-0.33	5.67	5.57	6.07	3.36
Abb Vie		NA	NA	NA	NA	NA	0.00	20.00	NA	20.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Abb Vie, License		NA	NA	NA	0.36	0.89	58.44	0.81	6.20	1.48	2.07	1.50	-12.33	23.65	5.29	NA	NA	NA	NA	NA	NA
Janssen Pharmaceuticals Inc, Reimbursement Revenue		0.00	0.00	0.05	0.46	0.66	1.03	1.01	1.03	1.28	1.31	1.32	1.44	1.63	1.84	NA	NA	NA	NA	NA	NA
Janssen Pharmaceuticals Inc, Upfront Payment Revenue		0.00	0.00	0.47	5.32	0.50	0.76	0.56	2.37	0.37	0.47	0.44	0.74	0.48	0.56	NA	NA	NA	NA	NA	NA
Janssen Pharmaceuticals Inc, Upfront Payment Revenue First Two Programs		NA	NA	NA	NA	NA	0.00	10.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Janssen Pharmaceuticals Inc, License		0.00	0.00	0.52	5.78	1.17	1.79	1.57	3.40	1.65	1.78	1.77	2.17	2.11	2.40	NA	NA	NA	NA	NA	NA
Revenue From Contract With Customer Including Assessed Tax		0.00	0.00	0.52	6.13	2.06	60.24	2.38	9.56	3.12	3.85	3.27	5.90	25.76	7.69	5.59	-0.33	5.67	5.57	6.07	3.36

Plots across concepts

Line plots across dimensions of each concept